Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer

British Journal of Cancer

Volumn 89, Issue 10, 2003, Pages 1987-1994

  Azria, D ^a,b   Larbouret, C ^a   Garambois, V ^a   Kramar, A ^b   Martineau, P ^c   Robert, B ^a   Ailleres N ^b   Ychou, M ^a,b   Dubois, J B ^a,b   Pelegrin A ^a,d  

^a INSERM   (France)

^b CENTRE VAL D AURELLE   (France)

^c CNRS   (France)

^d INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Bispecific antibody; Pancreas cancer; Radiation enhancement; Tumour necrosis factor alpha

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLONOGENESIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; HUMANS; PANCREATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION, IONIZING; S PHASE; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0348013434     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601362     Document Type: Article

References (52)

1. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU (1989) Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res 49: 4057-4061
2. Andre T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, Colonna M, Lotz JP, De Gramont A, Bellaiche A, Parc R, Touboul E, Izrael V (2000) Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 46: 903-911
3. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA (1987) Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974
4. Azria D, Dorvillius M, Gourgou S, Martineau P, Robert B, Pugnière M, Delard R, Ychou M, Dubois JB, Pèlegrin A (2003a) Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. Int J Radiat Oncol Biol Phys 55: 1363-1373
5. Azria D, Larbouret C, Martineau P, Robert B, Aillères N, Ychou M, Dubois JB, Pèlegrin A (2003b) A bispecific antibody against tumor necrosis factor alpha and carcinoembryonic antigen (CEA) to enhance radiation therapy in CEA-expressing digestive tumors. Int J Radiat Oncol Biol Phys, in press
6. Azria D, Ychou M, Jacot W, Thezenas S, Lemanski C, Senesse P, Prost P, Delard R, Masson B, Dubois JB (2002) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 25: 360-365
7. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670
8. Cavender D, Saegusa Y, Ziff M (1987) Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor. J Immunol 139: 1855-1860
9. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5: 1942-1951
10. Cooke SP, Pedley RB, Boden R, Begent RH, Chester KA (2002) In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjug Chem 13: 7-15
11. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino Jr MA, O'Connor JV (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163: 1433-1450
12. Dormond O, Lejeune FJ, Rüegg C (2002) Modulation of cdk2, cyclin D1, p161NK4a, p21 WAF and p27 Kip1 expression in endothelial cells by TNF/IFNγ. Anticancer Res 22: 3159-3163
13. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82: 8667-8671
14. Gasparri A, Moro M, Curnis F, Sacchi A, Pagano S, Veglia F, Casorati G, Siccardi AG, Dellabona P, Corti A (1999) Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res 59: 2917-2923
15. Gooch JL, Herrera RE, Yee D (2000) The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ 11: 335-342
16. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50: 7-33
17. Gridley DS, Archambeau JO, Andres MA, Mao XW, Wright K, Slater JM (1997) Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol Res 9: 217-227
18. Gridley DS, Glisson WC, Uhm JR (1994a) Interaction of tumour necrosis factor-alpha and radiation against human colon tumour cells. Ther Immunol 1: 25-31
19. Gridley DS, Hammond SN, Liwnicz BH (1994b) Tumor necrosis factor-alpha augments radiation effects against human colon tumor xenografts. Anticancer Res 14: 1107-1112
20. Gudjonsson B (1987) Cancer of the pancreas. 50 years of surgery. Cancer 60: 2284-2303
21. Hallahan DE, Beckett MA, Kufe D, Weichselbaum RR (1990) The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys 19: 69-74
22. Haskell CM, Buchegger F, Schreyer M, Carrel S, Mach JP (1983) Monoclonal antibodies to carcinoembryonic antigen: ionic strength as a factor in the selection of antibodies for immunoscintigraphy. Cancer Res 43: 3857-3864
23. Havell EA, Fiers W, North RJ (1988) The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167: 1067-1085
24. Helson L, Helson C, Green S (1979) Effects of murine tumor necrosis factor on heterotransplanted human tumors. Exp Cell Biol 47: 53-60
25. Kim DW, Andres ML, Li J, Kajioka EH, Miller GM, Seynhaeve AL, Ten Hagen TL, Gridley DS (2001) Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts. J Interferon Cytokine Res 21: 885-897
26. Kimura K, Bowen C, Spiegel S, Gelmann EP (1999) Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res 59: 1606-1614
27. Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, Haider K, Kwasny W, Locker G, Scheithauer W (2000) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 82: 98-103
28. Langley RE, Palayoor ST, Coleman CN, Bump EA (1993) Modifiers of radiation-induced apoptosis. Radiat Res 136: 320-326
29. Lejeune FJ, Ruegg C, Lienard D (1998) Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 10: 573-580
30. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60
31. Manetta A, Lucci J, Soopikian J, Granger G, Berman ML, DiSaia PJ (1990) In vitro cytotoxicity of human recombinant tumor necrosis factor alpha in association with radiotherapy in a human ovarian carcinoma cell line. Gynecol Oncol 38: 200-202
32. Matsuoka M, Nishimoto I, Asano S (1999) Interferon-gamma impairs physiologic downregulation of cyclin-dependent kinase inhibitor, p27Kip1, during G1 phase progression in macrophages. Exp Hematol 27: 203-209
33. Mavligit GM, Zukiwski AA, Charnsangavej C, Carrasco CH, Wallace S, Gutterman JU (1992) Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer 69: 557-561
34. Moritz T, Niederle N, Baumann J, May D, Kurschel E, Osieka R, Kempeni J, Schlick E, Schmidt CG (1989) Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother 29: 144-150
35. Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, Siccardi AG, Corti A (1997) Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 57: 1922-1928
36. Nishiguchi I, Willingham V, Milas L (1990) Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int J Radiat Oncol Biol Phys 18: 555-558
37. Ostensen ME, Thiele DL, Lipsky PE (1987) Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol 138: 4185-4191
38. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics, 1996. CA Cancer J Clin 46: 5-27
39. Robert B, Mach JP, Mani JC, Ychou M, Folli S, Artus JC, Pelegrin A (1996) Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer Res 56: 4758-4765
40. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4: 408-414
41. Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, Mano-Hirano Y, Sawasaki Y (1986) Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst 76: 1113-1121
42. Sersa G, Willingham V, Milas L (1988) Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer 42: 129-134
43. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei III E, Kufe DW (1988) Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 6: 344-350
44. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino Jr MA, Shepard HM (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945
45. Tabata Y, Noda Y, Matsui Y, Ikada Y (1999) Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination. J Control Release 59: 187-196
46. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH (1987) Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47: 2563-2570
47. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R, Douglass Jr HO, Chu TM (1986) Characterization of a new primary human pancreatic tumor line. Cancer Invest 4: 15-23
48. van der Schelling GP, Ijzermans JNM, Kok TC, Scheringa M, Marquet RL, Splinter TA, Jeekel J (1992) A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor. Eur J Cancer 28: 1073-1078
49. Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, Mauceri HJ (2002) Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 3: 665-671
50. Wüest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K (2002) TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 21: 4257-4265
51. Yamada T, Ohyama H (1988) Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). Int J Radiat Biol Relat Stud Phys Chem Med 53: 65-75
52. Zimmerman RJ, Chan A, Leadon SA (1989) Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 49: 1644-1648